Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan-Paul Bohn

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Memo|April 19, 2022
Agony of choice-selecting chronic lymphocytic leukemia treatment in 2022Jan-Paul Bohn
Memo|September 18, 2018
Current and evolving treatment strategies in adult immune thrombocytopeniaJan-Paul Bohn, Michael Steurer
Current Oncology Reports|September 8, 2023
Next-Generation Sequencing-Optimal Sequencing of Therapies in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)Florian Simon, Jan-Paul Bohn
Cancers|February 25, 2022
Treatment of Classic Hairy Cell Leukemia: Targeting Minimal Residual Disease beyond CladribineJan-Paul Bohn, Sascha Dietrich
Memo|July 19, 2016
Long-term treatment of hairy cell leukemia with interferon-α: still a viable therapeutic optionJan-Paul Bohn, Guenther Gastl, Michael Steurer
Targeted Oncology|January 30, 2016
Targeted Therapies for the Treatment of Brain Metastases in Solid TumorsJan-Paul Bohn, Georg Pall, Guenther Stockhammer, et al.
International Journal of Molecular Sciences|August 7, 2021
The Biology of Classic Hairy Cell LeukemiaJan-Paul Bohn, Stefan Salcher, Andreas Pircher, et al.
Cancers|March 10, 2022
Hairy Cell Leukemia Patients Have a Normal Life Expectancy-A 35-Year Single-Center Experience and Comparison with the General PopulationJan-Paul Bohn, Sabrina Neururer, Markus Pirklbauer, et al.
Therapeutic Advances in Hematology|August 4, 2022
Major cardiac surgery with recombinant FIX Fc fusion protein replacement in hemophilia B: a case reportJan-Paul Bohn, Anna Fiala, Sebastian Bachmann, et al.
Leukemia & Lymphoma|August 21, 2024
Reduced prognostic value of beta-2-microglobulin for time to first treatment in CLL patients with compromised kidney functionJan-Paul Bohn, Valentina Stolzlechner, Georg Göbel, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Memo|April 19, 2022
Agony of choice-selecting chronic lymphocytic leukemia treatment in 2022Jan-Paul Bohn
Memo|September 18, 2018
Current and evolving treatment strategies in adult immune thrombocytopeniaJan-Paul Bohn, Michael Steurer
Current Oncology Reports|September 8, 2023
Next-Generation Sequencing-Optimal Sequencing of Therapies in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)Florian Simon, Jan-Paul Bohn
Cancers|February 25, 2022
Treatment of Classic Hairy Cell Leukemia: Targeting Minimal Residual Disease beyond CladribineJan-Paul Bohn, Sascha Dietrich
Memo|July 19, 2016
Long-term treatment of hairy cell leukemia with interferon-α: still a viable therapeutic optionJan-Paul Bohn, Guenther Gastl, Michael Steurer
Targeted Oncology|January 30, 2016
Targeted Therapies for the Treatment of Brain Metastases in Solid TumorsJan-Paul Bohn, Georg Pall, Guenther Stockhammer, et al.
International Journal of Molecular Sciences|August 7, 2021
The Biology of Classic Hairy Cell LeukemiaJan-Paul Bohn, Stefan Salcher, Andreas Pircher, et al.
Cancers|March 10, 2022
Hairy Cell Leukemia Patients Have a Normal Life Expectancy-A 35-Year Single-Center Experience and Comparison with the General PopulationJan-Paul Bohn, Sabrina Neururer, Markus Pirklbauer, et al.
Therapeutic Advances in Hematology|August 4, 2022
Major cardiac surgery with recombinant FIX Fc fusion protein replacement in hemophilia B: a case reportJan-Paul Bohn, Anna Fiala, Sebastian Bachmann, et al.
Leukemia & Lymphoma|August 21, 2024
Reduced prognostic value of beta-2-microglobulin for time to first treatment in CLL patients with compromised kidney functionJan-Paul Bohn, Valentina Stolzlechner, Georg Göbel, et al.
Pageof 2